Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Ergomed – executive interview

Ergomed – executive interview

Ergomed — 2 videos in collection

More on this equity

In this interview, Ergomed’s CFO Richard Barfield runs through:

– The highlights of Ergomed’s recent trading update, with total H120 revenues increasing by 14.8% to £40.4m.
– How Ergomed has demonstrated significant resilience through the COVID-19 crisis.
– Some of the reasons behind the startling growth in Ergomed’s revenues over the last three years and how it intends to maintain that momentum.
– An overview of Ergomed’s M&A strategy.
– The outlook towards upcoming newsflow.

Ergomed is a global full-service CRO business with a core focus on the US and EU. It provides Phase I–III clinical services in addition to post-marketing pharmacovigilance (Phase IV) services through its PrimeVigilance division. The company is predominantly focused on oncology, orphan drugs, rare diseases and pharmacovigilance.

< Previous
Next >

You may also be interested in these:

Healthcare

Ergomed – Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free